Compare Cassava Sciences Inc (FLNA) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Shell PLC — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Shell PLC trades at $100.18 (market cap $284.34B). The key difference: Shell PLC is far larger — about 7216.8× Cassava Sciences Inc's market cap, and Shell PLC pays a 3.12% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Shell PLC for 90 Days on average.
| FLNA | SHEL | |
|---|---|---|
Market Cap | $39.40M | $284.34B |
Volume | 759,018 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $4.64 | $100.20 |
52-Week Low | $0.68 | $70.31 |
Typical Hold Time | 37 Days | 90 Days |
Enterprise Value | -$43.28M | $326.04B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.
The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.
Shell (SHEL) trades at $100.20, up 3.46% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and positive earnings surprises in recent quarters. Recent developments include the approval of LNG Canada Phase 2 expansion, doubling export capacity, and strategic portfolio optimization through asset sales. Financial metrics indicate solid profitability with 8.76% net income margin and attractive valuation at P/E of 11.08.
Shell presents a compelling investment case with strong LNG growth prospects and portfolio optimization driving future cash flows. However, declining revenue trends from $381.3B in 2022 to $266.9B in 2025 and volatile energy prices pose execution risks. Analyst consensus remains bullish with $102.53 price target, though current RSI levels suggest potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
